CELL AND GENE OUTSOURCING
Identify And Quantify AAV Fill States Using Analytical Ultracentrifugation
Explore how to implement analysis using sedimentation velocity analytical ultracentrifugation to characterize AAV size distributions and multiple detection wavelengths to identify various fill states in AAV preparation.
Selecting Containers For Sensitive And Costly Cell & Gene Therapies
Explore the challenges related to packaging of cell and gene therapy products and proven solutions to enable speed to market and compatibility, performance of packaging materials.
An End-To-End Industrialization Roadmap For Autologous Cell Therapy
Explore specificities and challenges, leveraging automation for scalability with the Cocoon® Platform, and building a vein-to-vein network to achieve ‘just-in-time’ delivery of therapies.
Minaris Advanced Therapies Philadelphia Campus Overview
Our Philadelphia Campus serves as a centralized hub for collaborative efforts, supporting numerous companies throughout the CGT pipeline, from initial research to commercial-scale manufacturing.
Keys To A Successful cGMP Manufacturing Operation Delivering CGTs
Uncover the secrets behind successes in commercializing and producing commercial cell and gene therapies, including establishing standards of every day, manufacturing operational excellence.
Critical Supply Chain And Logistics Considerations For Cell And Gene Therapy Management
Explore the unique challenges and complexities involved in key CGT logistics areas like donor and patient accessibility, critical raw materials management, and innovative temperature control equipment.
Optimization-By-Design — A Critical Factor In Viral Vector Scale Up
Learn how leveraging the expertise and capabilities of an experienced partner is a key factor in optimizing AAV processes using Design of Experiment (DoE), thereby reducing variability and risk.
Early Preclinical Development: A Successful Transition To cGMP Manufacturing
Explore the development steps that lead to an mRNA construct optimized for your requirements and that meets future-proof cGMP manufacturing requirements, thereby de-risking the development.
Tailored CMC Solutions That Meet Needs Of Novel Molecular Biologic Formats
Explore an integrated drug substance/drug product CMC strategy and technical case studies that provide insight into delivering product-specific solutions and enabling the acceleration of novel molecular formats.
Optimizing Monoclonal Antibody Manufacturing For Commercial Success
Strategically optimize your upstream and downstream processes and decrease the timeline from optimization to commercial manufacturing.
De-Risk Your Path To Clinic With An AAV Suspension Platform
Build a reliable, de-risked path to the clinic while avoiding unforeseen costs and compliance-related delays with advice from Suparna Sanyal, PhD, Head of Viral Vectors Commercial Development.
Get To Know Minaris Advanced Therapies Testing Services
Learn how we can help you move your pipeline forward, whether you manufacture with us at Minaris Advanced Therapies, in-house, or with one of our fellow CDMOs.
Cryopreservation Best Practices For Cell & Gene Therapy Source Material
Industry experts share their experiences, including why and how cellular source materials are cryopreserved and why experience across cell types and methods matters.
Mastering The Art Of Developing A Successful Bispecific Antibody
Learn innovative strategies to overcome the complexities of bispecific antibody development, from intelligent design to efficient purification techniques.
Building A Strong Safety Culture In The Biopharmaceutical Industry
Explore how fostering a strong safety culture — rooted in accountability, collaboration, and proactive risk management — can drive operational excellence and long-term success in biopharmaceuticals.
Improved And Rebalanced Plasmids To Ramp Up Your AAV Productivity
Growth in rAAV-based therapies is creating a need for dramatically increased production. Learn how AAV productivity can be optimized using platform technologies capable of affording significantly higher titers.
Meeting Needs And Exceeding Expectations Worldwide
Whether you are looking to optimize your existing formulations or require full-scale manufacturing solutions, Boehringer Ingelheim BioXcellence™ is dedicated to helping you realize your vision and deliver impactful therapies.
Early Developability And Analytical Toolbox For The Production Of Multi-Chain Biotherapeutics
In recent years, the number of biotherapeutic molecules requiring more complex assemblies has greatly increased. Typically, these multi-chain molecules are no longer compatible with platform approaches and require a more agile approach to early developability and method d...
Delivering Therapies To Patients At Scale And At Speed
Resilience is addressing a defining challenge: Biopharmaceutical manufacturing has not kept pace with scientific advancement, preventing new discoveries from reaching patients at speed or scale.
Candidate Screening And Feasibility Studies For Viral Gene Therapies
Create a simple, modular path to cGMP manufacturing that minimizes risk. Explore a strategic approach for early-stage development and how it can propel therapies to the clinic and the market.
A Robust And Scalable Suspension Platform For AAV Manufacturing
Review the demands for AAV manufacturing using a suspension process and the DOE-based strategy used to achieve a scalable process both in terms production and quality of AAV purified.
CRISPR Genome Editing Solutions From Discovery To Clinic
Examine how a partnership leveraging expertise in production for high-quality CRISPR gRNAs as well as cGMP manufacturing is supporting the clinical translation of CRISPR genome editing technologies.
Biopharmaceuticals Development And Manufacturing: Wide-Ranging Expertise And Vertically Integrated Service
The company’s wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art cGMP facilities while ensuring full process and product compliance at all stages of research, deve...
AAV Analytics: Key Considerations When Developing A Clinical Program
Finding partners with the necessary skills to optimize AAV processes is crucial for minimizing risk. Explore key considerations for advancing your therapy from concept to commercialization.
From Platform To Patient: Streamlining Gene Therapy Development
Explore how platform processes advance gene therapies, the impact of strong partnerships on patient access, and the future shaped by these collaborations.
Mastering The Journey From Initial Method Transfer To Successful Lot Release For Cell & Gene Therapies
View the webinar and learn how efficient project management and optimized communication are cornerstones of a successful transfer process.
Pioneering Solutions That Turn Hope Into Reality
The number of AAV-mediated therapies in clinical trials continues to rise, increasing demand for doses. A scalable platform is crucial to ensure a seamless transfer from pre-clinical to commercial.
How To Apply Quality By Design Principles To Cell And Gene Therapy Release Testing
Review how to develop and use QC assays that can facilitate both product and process understanding and control.
Accelerating Your Gene Therapy: Not All Platforms Are Created Equal
Standardized methods, materials, and analytics are critical for overcoming hurdles in the gene therapy space. Explore how a platform approach to fast-track AAVs can enhance quality and efficiency.
Cell & Gene Therapy Development: Characterization Of Cellular Starting Material
Watch to gain valuable insights into the characterization of cellular source material for the development and manufacture of cell and gene therapy-based products.